ClinicalTrials.gg
CompletedNCT04557735Updated Jan 12, 2026Results posted

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

A Phase 3 interventional study of Ravulizumab and Best Supportive Care in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 26 sites in 7 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Thrombotic Microangiopathies with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Thrombotic Microangiopathies · United States.

Enrollment
4th of 14
41 · median 24
Started
2020
with 2 others
Phase 3
7 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
6 of 20
Alexion Pharmaceuticals, Inc.

Among the 20 studies in Thrombotic Microangiopathies with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 3, and was the 11th registered.

Thrombotic Microangiopathies

52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.

Browse Thrombotic Microangiopathies studies →

Open to participants now

3 of the 20 studies in Thrombotic Microangiopathies with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Thrombotic Microangiopathies with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.

03

Conditions studied

  • Thrombotic Microangiopathy

Keywords

  • Thrombotic Microangiopathy (TMA)
  • Ultomiris
  • Ravulizumab
  • Hematopoietic Stem Cell Transplant
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 28 days of age up to \< 18 years of age at the time of signing the .
  2. Received within the past 12 months.
  3. Diagnosis of TMA that persists for at least 72 hours after initial management of any triggering agent/condition.
  4. A TMA diagnosis based on meeting the laboratory-based criteria during the Screening Period and/or ≤14 days prior to the Screening Period.
  5. Body weight ≥ 5 kilograms at Screening or ≤7 days prior to the start of the Screening Period (date of consent).
  6. Female participants of and male participants with female partners of childbearing potential must use highly effective .
  7. Participants must be vaccinated against meningococcal infections if clinically feasible. Participants who cannot receive meningococcal vaccine should receive antibiotic prophylaxis. Participants \<18 years of age must be re-vaccinated against Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae if clinically feasible.
  8. Participants or their legally authorized representative must be capable of giving signed informed consent or assent.

Exclusion criteria

Exclusion Criteria:

  1. Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency.
  2. Known Shiga toxin-related hemolytic uremic syndrome as demonstrated by positive test.
  3. Positive direct Coombs test indicative of a immune-mediated hemolysis not due to TMA.
  4. Clinical diagnosis of disseminated intravascular coagulation (DIC).
  5. Known bone marrow/graft failure for the current .
  6. Diagnosis of veno-occlusive disease (VOD) which is unresolved at the time of Screening.
  7. (HIV) infection.
  8. Unresolved meningococcal disease.
  9. Presence of sepsis requiring vasopressor support.
  10. Pregnancy or breastfeeding.
  11. to murine proteins or to 1 of the of Ravulizumab.
  12. Any ongoing or history of medical or psychological conditions unrelated to HSCT-TMA that could increase the risk to the participant or confound the outcome of the study.
  13. Respiratory failure requiring mechanical ventilation.
  14. Previously or currently treated with a complement inhibitor.
  15. Participation in an interventional treatment study of any therapy for TMA.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Ravulizumab plus Best Supportive Care

    Participants will receive ravulizumab plus Best Supportive Care as background therapy.

    Drug: Ravulizumab · Other: Best Supportive Care

Interventions

  • Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.

    Also known as: Ultomiris

  • OtherBest Supportive Care

    Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

06

What researchers measure

Primary outcomes

  1. Participants With Thrombotic Microangiopathy (TMA) Response

    The criteria for TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, with no criteria failures or more than 1 missed scheduled visit in between. Additionally, all intervals in which the criteria were met must overlap for at least 1 day.

    Time frame: Up to Week 26

Secondary outcomes

  1. Time to TMA Response During the 26-Week Treatment Period

    Time to TMA response was defined as the time from first infusion to the first time point at which all criteria for TMA response was met. Participants were assigned as responders at the time of their TMA response and were censored at the earlier of last assessment with all 3 TMA response components available (including measurements collected after treatment discontinuation), or death if they did not respond by then. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

    Time frame: Day 1 through Week 26

  2. Participants With Hematologic Response

    Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.

    Time frame: Up to Week 26

  3. Time to Hematologic Response During the 26-Week Treatment Period

    Time to Hematologic response was defined as the time from first infusion to the first time point at which all criteria for hematologic response was met. Participants were assigned as responders at the time of their response and were censored at their discontinuation time or at the end of available follow-up if they did not respond by then. Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.

    Time frame: Day 1 through Week 26

  4. Participants With Hemoglobin Response

    Hemoglobin response was defined as the ability to maintain hemoglobin ≥ 10 g/dL without RBC transfusion support. The criterion must have been met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without RBC transfusion support during the prior 7 days.

    Time frame: Up to Week 26

  5. Participants With Platelet Response

    Normalization of platelet count was defined as baseline platelet count ≤ 50000 mm\^3 or \> 50000 mm\^3, absolute platelet count \> 50000 mm\^3 or \>=50% increase in platelet count without transfusion support during the prior 7 days.

    Time frame: Up to Week 26

  6. Participants With Partial TMA Response

    Partial response was defined as a participant meeting at least 1, but not all, criteria for TMA response. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH, (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

    Time frame: Up to Week 26

  7. Participants With Loss of TMA Response

    Loss of response occurred when a participant who had previously achieved a TMA response failed to meet criteria for one or more components of TMA response at a subsequent visit in treatment period. At least one parameter must fail to meet response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

    Time frame: Up to Week 26

  8. Duration of TMA Response Through Week 52

    This analysis includes data for each participant after TMA response through final follow-up. Participants with TMA response who do not experience these events are censored at their end of study date. TMA response required following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. The estimate is calculated based on Kaplan-Meier method.

    Time frame: Day 1 through Week 52

  9. Participants With TMA Relapse

    For participants that meet criteria for TMA response during 26-week Treatment Period, TMA relapse is defined as evidence of worsening hematologic and renal dysfunction due to TMA during post-treatment Follow-up Period that requires treatment intervention, as determined by Investigator. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

    Time frame: Up to Week 52

  10. Overall Survival

    The Kaplan-Meier method was used to measure overall survival estimate. Overall survival was calculated from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Week 52, or their last known date alive.

    Time frame: Day 1 through Week 52

  11. Non-relapse Mortality During the 52-Week Treatment Period

    Cumulative incidence was estimated using a competing risk model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease progression or relapse.

    Time frame: Day 1 through Week 52

07

Results

Posted Jan 12, 2026

Participant flow

Treatment Period (26 Weeks)
Participant flow — Treatment Period (26 Weeks)
MilestoneRavulizumab
Started41
Received at least 1 dose of study drug41
Completed29
Not completed12
Withdrew: Withdrawal by subject1
Withdrew: Physician decision4
Withdrew: Death5
Withdrew: Adverse event2
Follow-Up Period (26 Weeks)
Participant flow — Follow-Up Period (26 Weeks)
MilestoneRavulizumab
Started29
Completed24
Not completed5
Withdrew: Physician decision1
Withdrew: Death4

Outcome measures

PrimaryParticipants With Thrombotic Microangiopathy (TMA) Response

The criteria for TMA response were: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of lactate dehydrogenase (LDH, defined as LDH ≤ upper limit of normal \[ULN\]) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, with no criteria failures or more than 1 missed scheduled visit in between. Additionally, all intervals in which the criteria were met must overlap for at least 1 day.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Thrombotic Microangiopathy (TMA) Response
ParticipantsRavulizumab
Participants With Thrombotic Microangiopathy (TMA) Response7
SecondaryTime to TMA Response During the 26-Week Treatment Period

Time to TMA response was defined as the time from first infusion to the first time point at which all criteria for TMA response was met. Participants were assigned as responders at the time of their TMA response and were censored at the earlier of last assessment with all 3 TMA response components available (including measurements collected after treatment discontinuation), or death if they did not respond by then. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

Time frame:
Day 1 through Week 26
Reported as:
Median · days
Time to TMA Response During the 26-Week Treatment Period
daysRavulizumab
Time to TMA Response During the 26-Week Treatment PeriodNA (154.0 to NA)
SecondaryParticipants With Hematologic Response

Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Hematologic Response
ParticipantsRavulizumab
Participants With Hematologic Response10
SecondaryTime to Hematologic Response During the 26-Week Treatment Period

Time to Hematologic response was defined as the time from first infusion to the first time point at which all criteria for hematologic response was met. Participants were assigned as responders at the time of their response and were censored at their discontinuation time or at the end of available follow-up if they did not respond by then. Hematologic response required the following: (1) Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days and (2) Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes.

Time frame:
Day 1 through Week 26
Reported as:
Median · days
Time to Hematologic Response During the 26-Week Treatment Period
daysRavulizumab
Time to Hematologic Response During the 26-Week Treatment PeriodNA (154.0 to NA)
SecondaryParticipants With Hemoglobin Response

Hemoglobin response was defined as the ability to maintain hemoglobin ≥ 10 g/dL without RBC transfusion support. The criterion must have been met at 2 separate assessments obtained at least 24 hours apart, and any measurement in between, and without RBC transfusion support during the prior 7 days.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Hemoglobin Response
ParticipantsRavulizumab
Participants With Hemoglobin Response17
SecondaryParticipants With Platelet Response

Normalization of platelet count was defined as baseline platelet count ≤ 50000 mm\^3 or \> 50000 mm\^3, absolute platelet count \> 50000 mm\^3 or \>=50% increase in platelet count without transfusion support during the prior 7 days.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Platelet Response
ParticipantsRavulizumab
Participants With Platelet Response24
SecondaryParticipants With Partial TMA Response

Partial response was defined as a participant meeting at least 1, but not all, criteria for TMA response. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH, (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Partial TMA Response
ParticipantsRavulizumab
Participants With Partial TMA Response22
SecondaryParticipants With Loss of TMA Response

Loss of response occurred when a participant who had previously achieved a TMA response failed to meet criteria for one or more components of TMA response at a subsequent visit in treatment period. At least one parameter must fail to meet response criteria at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Participants With Loss of TMA Response
ParticipantsRavulizumab
Participants With Loss of TMA Response2
SecondaryDuration of TMA Response Through Week 52

This analysis includes data for each participant after TMA response through final follow-up. Participants with TMA response who do not experience these events are censored at their end of study date. TMA response required following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline. The estimate is calculated based on Kaplan-Meier method.

Time frame:
Day 1 through Week 52
Reported as:
Median · days
Duration of TMA Response Through Week 52
daysRavulizumab
Duration of TMA Response Through Week 52NA (22.0 to NA)
SecondaryParticipants With TMA Relapse

For participants that meet criteria for TMA response during 26-week Treatment Period, TMA relapse is defined as evidence of worsening hematologic and renal dysfunction due to TMA during post-treatment Follow-up Period that requires treatment intervention, as determined by Investigator. TMA response required the following: 1. Normalization of platelet count (defined as platelet count ≥ 50000 mm\^3 or \>=50% increase in platelet count) without transfusion support during the prior 7 days. 2. Normalization of LDH (defined as LDH ≤ULN) and absence of schistocytes. 3. At least 50% reduction in protein/creatinine ratio from baseline.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Participants With TMA Relapse
ParticipantsRavulizumab
Participants With TMA Relapse0
SecondaryOverall Survival

The Kaplan-Meier method was used to measure overall survival estimate. Overall survival was calculated from date of treatment start to date of a documented death event (death due to any cause) or date of censoring. Participants who survived were censored at the earliest of an additional hematopoietic stem cell transplant (HSCT), Week 52, or their last known date alive.

Time frame:
Day 1 through Week 52
Reported as:
Number · proportion of participants
Overall Survival
proportion of participantsRavulizumab
Overall Survival0.734 (0.560 to 0.847)
SecondaryNon-relapse Mortality During the 52-Week Treatment Period

Cumulative incidence was estimated using a competing risk model. Non-relapse mortality was defined as a participant's death due to any cause during the study, with the exception of death due to underlying disease progression or relapse.

Time frame:
Day 1 through Week 52
Reported as:
Number · proportion of participants
Non-relapse Mortality During the 52-Week Treatment Period
proportion of participantsRavulizumab
Non-relapse Mortality During the 52-Week Treatment Period0.184 (0.079 to 0.322)

Adverse events

Collected over Day 1 up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Period: Ravulizumab6/41 (14.6%)30/41 (73.2%)41/41 (100%)
Follow-up Period: Ravulizumab4/29 (13.8%)15/29 (51.7%)23/29 (79.3%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventTreatment Period: RavulizumabFollow-up Period: Ravulizumab
Febrile neutropeniaBlood and lymphatic system disorders3/410/29
Multiple organ dysfunction syndromeGeneral disorders3/410/29
SeizureNervous system disorders3/411/29
PyrexiaGeneral disorders2/412/29
Device related bacteraemiaInfections and infestations0/412/29
InfluenzaInfections and infestations0/412/29
Pericardial effusionCardiac disorders2/410/29
COVID-19Infections and infestations2/410/29
Gastroenteritis clostridialInfections and infestations2/410/29
Septic shockInfections and infestations2/410/29
Most frequent other events
Showing 10 of 53
Most frequent other events
EventTreatment Period: RavulizumabFollow-up Period: Ravulizumab
HeadacheNervous system disorders11/413/29
DiarrhoeaGastrointestinal disorders10/412/29
PyrexiaGeneral disorders10/416/29
Abdominal painGastrointestinal disorders9/413/29
VomitingGastrointestinal disorders8/410/29
Alanine aminotransferase increasedInvestigations8/411/29
Aspartate aminotransferase increasedInvestigations7/411/29
HypokalaemiaMetabolism and nutrition disorders7/410/29
CoughRespiratory, thoracic and mediastinal disorders7/414/29
AnaemiaBlood and lymphatic system disorders6/410/29

Baseline characteristics

Safety set included all participants who signed the informed consent and received at least 1 dose of ravulizumab.

Age, Continuous
Age, Continuous(years)Ravulizumab
Mean7.6 ± 5.57
Sex: Female, Male
Sex: Female, Male(Participants)Ravulizumab
Female21
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ravulizumab
Hispanic or Latino5
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ravulizumab
American Indian or Alaska Native0
Asian11
Native Hawaiian or Other Pacific Islander0
Black or African American2
White22
More than one race6
Unknown or Not Reported0
08

Study locations

26 sites
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Dallas, Texas 75235, United States
  • Research Site
    Salt Lake City, Utah 84108, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    Haifa, 91096, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 4920235, Israel
  • Research Site
    Ramat Gan, 5265601, Israel
  • Research Site
    Roma, 00165, Italy
  • Research Site
    Fukushima, 960-1295, Japan
  • Research Site
    Kobe, 650-0047, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Osaka, 534-0021, Japan
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 5505, South Korea
  • Research Site
    Barcelona, 08041, Spain
  • Research Site
    Esplugues de Llobregat, 8950, Spain
  • Research Site
    Madrid, 28046, Spain
  • Research Site
    Salamanca, 37007, Spain
  • Research Site
    Birmingham, B4 6NH, United Kingdom
  • Research Site
    Bristol, BS2 8BJ, United Kingdom
  • Research Site
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Nov 2024, 47 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2020
First posted
Sep 22, 2020
StartActual
Dec 7, 2020
Primary completionActual
Nov 26, 2024
CompletionActual
May 27, 2025
Results first posted
Jan 12, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04557735
Responsible party
Sponsor
First posted
Sep 22, 2020
Start date
Dec 7, 2020
Primary completion
Nov 26, 2024
Completion
May 27, 2025
Results posted
Jan 12, 2026
Last update
Jan 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion